Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Titles
NEW
 Top 50 Non-Healthcare Titles
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Leukocyte Adhesion Deficiency Management Global Market Report 2025
Request Sample Buy Now
Global Leukocyte Adhesion Deficiency Management Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Leukocyte Adhesion Deficiency Management Global Market Report 2025

By Treatment (Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors), By Diagnosis (Blood Test, Genetic Testing, Biopsy, Other Types), By End-Users (Hospitals, Specialty Clinics, Other End-Users ) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Leukocyte Adhesion Deficiency Management Market Overview

• Leukocyte Adhesion Deficiency Management market size has reached to $8.07 billion in 2024

• Expected to grow to $11.28 billion in 2029 at a compound annual growth rate (CAGR) of 7%

• Growth Driver: Leukocyte Adhesion Deficiency Management Market Grows In Response To Rising Prevalence Of Primary Immunodeficiency.

• Market Trend: Advancements In Leukocyte Adhesion Deficiency Management Lentiviral Vector-Based Gene Therapy Shows Promising Results

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leukocyte Adhesion Deficiency Management Market?

Leukocyte adhesion deficiency (LAD) is a rare genetic disorder affecting the immune system's ability to fight infections. It is characterized by a defect in the adhesion (stickiness) of white blood cells, specifically neutrophils, essential for the body's defense against bacteria and fungi. Management of leukocyte adhesion deficiency typically involves a multidisciplinary approach and focuses on preventing and treating infections and addressing the underlying immune system dysfunction.

The main types of treatment in leukocyte adhesion deficiency management are hematopoietic stem cell transplantation, recombinant human interferon-gamma treatment, prophylactic immunoglobulin therapy, antimicrobial therapy, prophylactic therapy, fucose supplementation, monoclonal antibodies, and coagulation factors. Hematopoietic stem cell transplantation refers to a medical procedure where stem cells from the bone marrow or blood are transplanted into a patient to replace damaged or diseased blood-forming cells. Treatment and diagnostics such as blood tests, genetic testing, biopsies, and others are provided by end users such as hospitals, specialty clinics, and others.

Leukocyte Adhesion Deficiency Management Market Size and growth rate 2025 to 2029: Graph

What Is The Leukocyte Adhesion Deficiency Management Market Size 2025 And Growth Rate?

The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $8.07 billion in 2024 to $8.59 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increased awareness and education, genetic testing advancements, orphan drug designations, global health policies, patient advocacy groups, pediatric healthcare advancements.

What Is The Leukocyte Adhesion Deficiency Management Market Growth Forecast?

The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $11.28 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to precision medicine approaches, emergence of novel therapeutics, expanded genetic testing accessibility, patient-centric drug development, advancements in immunomodulatory therapies. Major trends in the forecast period include stem cell transplantation innovations, integration of supportive therapies, telemedicine for remote consultations, collaboration and research networks, integration of biomarker technologies.

The forecast of 7.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. immunology centers by driving up the cost of hematopoietic stem cell transplantation supplies and recombinant CD18 therapies imported from Sweden and Israel, exacerbating treatment delays for rare immunodeficiency disorders and increasing pediatric specialty care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Leukocyte Adhesion Deficiency Management Market Segmented?

1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors

2) By Diagnosis: Blood Test, Genetic Testing, Biopsy, Other Types

3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Hematopoietic Stem Cell Transplantation: Related Donor Transplant, Unrelated Donor Transplant

2) By Recombinant Human Interferon-Gamma Treatment: Standard Dosing, Customized Dosing

3) By Prophylactic Immunoglobulin Therapy: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

4) By Antimicrobial Therapy: Antibiotics, Antifungal Treatments

5) By Prophylactic Therapy: Vaccination Strategies, Infection Prevention Protocols

6) By Fucose Supplementation: Oral Supplements, Intravenous Supplements

7) By Monoclonal Antibodies: Specific Target Monoclonal Antibodies, Combination Therapy Monoclonal Antibodies

8) By Coagulation Factors: Factor Replacement Therapies, Novel Coagulation Agents

What Is Driving The Leukocyte Adhesion Deficiency Management Market? Leukocyte Adhesion Deficiency Management Market Grows In Response To Rising Prevalence Of Primary Immunodeficiency.

The rising prevalence of primary immunodeficiency is expected to propel the growth of the leukocyte adhesion deficiency management market going forward. Primary immunodeficiency (PID) is a group of inherited disorders that weaken the body's immune system, making individuals more susceptible to infections and illnesses due to defects in their immune responses. Management of leukocyte adhesion deficiency benefits primary immunodeficiency by advancing the understanding of immune system disorders and potentially leading to improved diagnostic tools and therapies to help both conditions. For instance, in April 2023, according to the Peace Hospital, an India-based multi-specialty hospital, the data collected from World Primary Immunodeficiency (WPI) Awareness Week 2023 shows that primary immunodeficiency (PI) affects an estimated 60 lakh people globally, and 70% to 90% of people have undiagnosed primary immunodeficiency. Therefore, the rising prevalence of primary immunodeficiency will drive the growth of the leukocyte adhesion deficiency management industry.

What Is Driving The Leukocyte Adhesion Deficiency Management Market? Rising Prevalence Of Spinal Cord Injuries Fuels Growth In Leukocyte Adhesion Deficiency Management Market

The increasing prevalence of spinal cord injuries is expected to propel the growth of the leukocyte adhesion deficiency management market going forward. Spinal cord injury is a condition that occurs when there is damage to any part of the spinal cord or nerves at the end of the spinal canal (cauda equina). Spinal cord injury can lead to autonomic dysfunction, including hyperhidrosis. It is related to sympathetic overactivity of the cephalad portion of the spinal cord immediately below the zone of injury. For instance, in March 2022, according to the National Spinal Cord Injury Statistical Center (NSCISC), a US-based department that supports and directs the collection, management, and analysis of spinal cord injury research databases, IT is estimated that the annual incidence of traumatic spinal cord injury (SCI) is approximately 54 cases per one million people in the United States, which equals about 18,000 new SCI (spinal cord injury) cases each year. Further, the estimated number of people with SCI living in the United States is approximately 299,000, ranging from 253,000 to 378,000. Therefore, the increasing prevalence of spinal cord injuries drives the growth of the leukocyte adhesion deficiency management industry.

Who Are The Major Players In The Global Leukocyte Adhesion Deficiency Management Market?

Major companies operating in the leukocyte adhesion deficiency management market report are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline PLC, Gilead Sciences Inc., Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd., Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc., Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.

What Are The Key Trends Of The Global Leukocyte Adhesion Deficiency Management Market? Advancements In Leukocyte Adhesion Deficiency Management Lentiviral Vector-Based Gene Therapy Shows Promising Results

Major companies operating in the leukocyte adhesion deficiency management market are developing lentiviral vector-based gene therapy technology to improve targeted treatments and enhance patient outcomes. Lentiviral vector-based gene therapy offers a targeted approach in leukocyte adhesion deficiency management by delivering corrective genes directly into cells, potentially restoring immune function.For instance, in February 2024, Rocket Pharmaceuticals, a US-based biotechnology company, launched kresladi (marnetegragene autotemcel) for treating severe leukocyte adhesion deficiency-I (LAD-I). In a Phase 1/2 study, IT achieved 100% survival at 12 months, significantly reducing infections and improving symptoms. Kresladi offers a groundbreaking option in the LAD management market, addressing critical unmet needs.

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Leukocyte Adhesion Deficiency Management Market? JMF And Veritas Intercontinental Join Forces For Genome Sequencing Advancements In Primary Immunodeficiency

In February 2023, Jeffrey Modell Foundation (JMF), a US-based nonprofit company for primary immunodeficiency, collaborated with Veritas Intercontinental to advance genome and exome sequencing for immunological disorders. The collaboration aims to enhance precise diagnosis and treatment by globally identifying gene abnormalities in primary immunodeficiency, such as leukocyte adhesion deficiency. Veritas Intercontinental is a Spain-based healthcare solutions company specializing in genome sequencing and analytic services.

Regional Outlook For The Global Leukocyte Adhesion Deficiency Management Market

North America was the largest region in the leukocyte adhesion deficiency management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Leukocyte Adhesion Deficiency Management Market?

The leukocyte adhesion deficiency management market consists of revenues earned by entities by providing services such as gene therapy, granulocyte transfusions, nutrition, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The leukocyte adhesion deficiency management market also includes sales of antibiotics such as trimethoprim and sulfamethoxazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Leukocyte Adhesion Deficiency Management Industry?

The leukocyte adhesion deficiency management market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leukocyte adhesion deficiency management industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Leukocyte Adhesion Deficiency Management Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $8.59 billion
Revenue Forecast In 2034 $11.28 billion
Growth Rate CAGR of 7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors
2) By Diagnosis: Blood Test, Genetic Testing, Biopsy, Other Types
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Hematopoietic Stem Cell Transplantation: Related Donor Transplant, Unrelated Donor Transplant
2) By Recombinant Human Interferon-Gamma Treatment: Standard Dosing, Customized Dosing
3) By Prophylactic Immunoglobulin Therapy: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
4) By Antimicrobial Therapy: Antibiotics, Antifungal Treatments
5) By Prophylactic Therapy: Vaccination Strategies, Infection Prevention Protocols 6) By Fucose Supplementation: Oral Supplements, Intravenous Supplements 7) By Monoclonal Antibodies: Specific Target Monoclonal Antibodies, Combination Therapy Monoclonal Antibodies 8) By Coagulation Factors: Factor Replacement Therapies, Novel Coagulation Agents
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Leukocyte Adhesion Deficiency Management Market Characteristics

3. Leukocyte Adhesion Deficiency Management Market Trends And Strategies

4. Leukocyte Adhesion Deficiency Management Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Leukocyte Adhesion Deficiency Management Growth Analysis And Strategic Analysis Framework

5.1. Global Leukocyte Adhesion Deficiency Management PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Leukocyte Adhesion Deficiency Management Market Growth Rate Analysis

5.4. Global Leukocyte Adhesion Deficiency Management Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Leukocyte Adhesion Deficiency Management Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Leukocyte Adhesion Deficiency Management Total Addressable Market (TAM)

6. Leukocyte Adhesion Deficiency Management Market Segmentation

6.1. Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hematopoietic Stem Cell Transplantation

Recombinant Human Interferon-Gamma Treatment

Prophylactic Immunoglobulin Therapy

Antimicrobial Therapy

Prophylactic Therapy

Fucose Supplementation

Monoclonal Antibodies

Coagulation Factors

6.2. Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Blood Test

Genetic Testing

Biopsy

Other Types

6.3. Global Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Other End-Users

6.4. Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Hematopoietic Stem Cell Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Related Donor Transplant

Unrelated Donor Transplant

6.5. Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Recombinant Human Interferon-Gamma Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Standard Dosing

Customized Dosing

6.6. Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Prophylactic Immunoglobulin Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous Immunoglobulin (IVIG)

Subcutaneous Immunoglobulin (SCIG)

6.7. Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Antimicrobial Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antibiotics

Antifungal Treatments

6.8. Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Prophylactic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Vaccination Strategies

Infection Prevention Protocols

6.9. Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Fucose Supplementation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral Supplements

Intravenous Supplements

6.10. Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Specific Target Monoclonal Antibodies

Combination Therapy Monoclonal Antibodies

6.11. Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Coagulation Factors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Factor Replacement Therapies

Novel Coagulation Agents

7. Leukocyte Adhesion Deficiency Management Market Regional And Country Analysis

7.1. Global Leukocyte Adhesion Deficiency Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Leukocyte Adhesion Deficiency Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Leukocyte Adhesion Deficiency Management Market

8.1. Asia-Pacific Leukocyte Adhesion Deficiency Management Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Leukocyte Adhesion Deficiency Management Market

9.1. China Leukocyte Adhesion Deficiency Management Market Overview

9.2. China Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Leukocyte Adhesion Deficiency Management Market

10.1. India Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Leukocyte Adhesion Deficiency Management Market

11.1. Japan Leukocyte Adhesion Deficiency Management Market Overview

11.2. Japan Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Leukocyte Adhesion Deficiency Management Market

12.1. Australia Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Leukocyte Adhesion Deficiency Management Market

13.1. Indonesia Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Leukocyte Adhesion Deficiency Management Market

14.1. South Korea Leukocyte Adhesion Deficiency Management Market Overview

14.2. South Korea Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Leukocyte Adhesion Deficiency Management Market

15.1. Western Europe Leukocyte Adhesion Deficiency Management Market Overview

15.2. Western Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Leukocyte Adhesion Deficiency Management Market

16.1. UK Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Leukocyte Adhesion Deficiency Management Market

17.1. Germany Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Leukocyte Adhesion Deficiency Management Market

18.1. France Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Leukocyte Adhesion Deficiency Management Market

19.1. Italy Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Leukocyte Adhesion Deficiency Management Market

20.1. Spain Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Leukocyte Adhesion Deficiency Management Market

21.1. Eastern Europe Leukocyte Adhesion Deficiency Management Market Overview

21.2. Eastern Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Leukocyte Adhesion Deficiency Management Market

22.1. Russia Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Leukocyte Adhesion Deficiency Management Market

23.1. North America Leukocyte Adhesion Deficiency Management Market Overview

23.2. North America Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Leukocyte Adhesion Deficiency Management Market

24.1. USA Leukocyte Adhesion Deficiency Management Market Overview

24.2. USA Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Leukocyte Adhesion Deficiency Management Market

25.1. Canada Leukocyte Adhesion Deficiency Management Market Overview

25.2. Canada Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Leukocyte Adhesion Deficiency Management Market

26.1. South America Leukocyte Adhesion Deficiency Management Market Overview

26.2. South America Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Leukocyte Adhesion Deficiency Management Market

27.1. Brazil Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Leukocyte Adhesion Deficiency Management Market

28.1. Middle East Leukocyte Adhesion Deficiency Management Market Overview

28.2. Middle East Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Leukocyte Adhesion Deficiency Management Market

29.1. Africa Leukocyte Adhesion Deficiency Management Market Overview

29.2. Africa Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Leukocyte Adhesion Deficiency Management Market Competitive Landscape And Company Profiles

30.1. Leukocyte Adhesion Deficiency Management Market Competitive Landscape

30.2. Leukocyte Adhesion Deficiency Management Market Company Profiles

30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Gilead Sciences Inc Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Teva Pharmaceuticals Industries Limited Overview, Products and Services, Strategy and Financial Analysis

31. Leukocyte Adhesion Deficiency Management Market Other Major And Innovative Companies

31.1. CSL Behring LLC

31.2. Vertex Pharmaceuticals Inc.

31.3. Grifols International S.A.

31.4. Aurobindo Pharma Ltd.

31.5. BioMarin Pharmaceutical Inc.

31.6. Cadila Healthcare Ltd.

31.7. Ipca Laboratories Ltd

31.8. Sana Biotechnology Inc.

31.9. Rocket Pharmaceuticals Inc.

31.10. PT Sanbe Farma

31.11. Magenta Therapeutics Inc

31.12. Avalo Therapeutics Inc.

31.13. Aspen Neuroscience Inc.

31.14. Sandoz International GmbH

31.15. Orpha Labs Inc.

32. Global Leukocyte Adhesion Deficiency Management Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Leukocyte Adhesion Deficiency Management Market

34. Recent Developments In The Leukocyte Adhesion Deficiency Management Market

35. Leukocyte Adhesion Deficiency Management Market High Potential Countries, Segments and Strategies

35.1 Leukocyte Adhesion Deficiency Management Market In 2029 - Countries Offering Most New Opportunities

35.2 Leukocyte Adhesion Deficiency Management Market In 2029 - Segments Offering Most New Opportunities

35.3 Leukocyte Adhesion Deficiency Management Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

Need tailored insights? Customise this report to fit your business goals.

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Hematopoietic Stem Cell Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Recombinant Human Interferon-Gamma Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Prophylactic Immunoglobulin Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Antimicrobial Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Prophylactic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Fucose Supplementation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Coagulation Factors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Leukocyte Adhesion Deficiency Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Global Leukocyte Adhesion Deficiency Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 82: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 83: Novartis AG Financial Performance
  • Table 84: GlaxoSmithKline Plc Financial Performance
  • Table 85: Gilead Sciences Inc Financial Performance
  • Table 86: Teva Pharmaceuticals Industries Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Hematopoietic Stem Cell Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Recombinant Human Interferon-Gamma Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Prophylactic Immunoglobulin Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Antimicrobial Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Prophylactic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Fucose Supplementation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Leukocyte Adhesion Deficiency Management Market, Sub-Segmentation Of Coagulation Factors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Leukocyte Adhesion Deficiency Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Global Leukocyte Adhesion Deficiency Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 82: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 83: Novartis AG Financial Performance
  • Figure 84: GlaxoSmithKline Plc Financial Performance
  • Figure 85: Gilead Sciences Inc Financial Performance
  • Figure 86: Teva Pharmaceuticals Industries Limited Financial Performance

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

Read More About Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Read More About Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Key Market Drivers, Trends, and Forecast for the Global Continence Care Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Continence Care Industry

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Explore future trends in the global pharma and biotech CRM software market. Understand market growth, drivers, and industry outlook through 2034.

Read More About Explore future trends in the global pharma and biotech CRM software market. Understand market growth, drivers, and industry outlook through 2034.

Blood Warmers Global Market Report 2024 – By Type (Portable blood warmers, Non-portable blood warmers), By Application (Surgery, Acute care, Newborn care, Homecare, Other Applications), By End-User (Hospitals Or Clinics,...

View Report

Application Performance Monitoring Global Market Report 2025 – By Component (Software, Services), By Deployment (Cloud, On-Premises), By Enterprise Size (Small And Medium Enterprises (SMEs), Large Enterprises), By Applic...

View Report

Blepharoplasty Global Market Report 2025 – By Type (Upper Eyelid Blepharoplasty, Lower Eyelid Blepharoplasty, Combination Eyelid Surgery), By Gender (Female, Male), By End-User (Hospitals, Clinics, Ambulatory Surgical Ce...

View Report

Colorectal Cancer Molecular Diagnostics Global Market Report 2025 – By Type (Instruments, Reagents And Kits, Services), By Technology (Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediate...

View Report

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2025 – By Drug Type (Palbociclib (Ibrance), Ribociclib (Kisqali), Abermaciclib (Verzenio)), By Patient (Pre-Menopausal, Post-Menopausal, Other Patien...

View Report

Fire Truck Global Market Report 2025 – By Product (Aerial Ladder Trucks, Aerial Platform Trucks, Other Products), By Propulsion Type (Internal Combustion Engine (ICE), Electric), By Application (Residential And Commercia...

View Report

Deionized Water Systems Global Market Report 2025 – By Type (Two Bed Deionized Water System, Mixed Bed Deionized Water System, Electrodeionization Water System), By Distribution Channel (Direct Sales, Distributors), By E...

View Report

Frequently Asked Questions

Leukocyte adhesion deficiency (LAD) is a rare genetic disorder affecting the immune system's ability to fight infections. It is characterized by a defect in the adhesion (stickiness) of white blood cells, specifically neutrophils, essential for the body's defense against bacteria and fungi. Management of leukocyte adhesion deficiency typically involves a multidisciplinary approach and focuses on preventing and treating infections and addressing the underlying immune system dysfunction. For further insights on this market, request a sample here

The market major growth driver - Leukocyte Adhesion Deficiency Management Market Grows In Response To Rising Prevalence Of Primary Immunodeficiency.. For further insights on this market, request a sample here

The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $8.07 billion in 2024 to $8.59 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increased awareness and education, genetic testing advancements, orphan drug designations, global health policies, patient advocacy groups, pediatric healthcare advancements. The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to " $11.28 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to precision medicine approaches, emergence of novel therapeutics, expanded genetic testing accessibility, patient-centric drug development, advancements in immunomodulatory therapies. Major trends in the forecast period include stem cell transplantation innovations, integration of supportive therapies, telemedicine for remote consultations, collaboration and research networks, integration of biomarker technologies. For further insights on this market, request a sample here

The leukocyte adhesion deficiency managementmarket covered in this report is segmented –
1) By Treatment: Hematopoietic Stem Cell Transplantation; Recombinant Human Interferon-Gamma Treatment; Prophylactic Immunoglobulin Therapy; Antimicrobial Therapy; Prophylactic Therapy; Fucose Supplementation; Monoclonal Antibodies; Coagulation Factors
2) By Diagnosis: Blood Test; Genetic Testing; Biopsy; Other Types
3) By End-Users: Hospitals; Specialty Clinics; Other End-Users Subsegments:
1) By Hematopoietic Stem Cell Transplantation: Related Donor Transplant; Unrelated Donor Transplant
2) By Recombinant Human Interferon-Gamma Treatment: Standard Dosing; Customized Dosing
3) By Prophylactic Immunoglobulin Therapy: Intravenous Immunoglobulin (IVIG); Subcutaneous Immunoglobulin (SCIG)
4) By Antimicrobial Therapy: Antibiotics; Antifungal Treatments
5) By Prophylactic Therapy: Vaccination Strategies; Infection Prevention Protocols
6) By Fucose Supplementation: Oral Supplements; Intravenous Supplements
7) By Monoclonal Antibodies: Specific Target Monoclonal Antibodies; Combination Therapy Monoclonal Antibodies
8) By Coagulation Factors: Factor Replacement Therapies; Novel Coagulation Agents For further insights on this market, request a sample here

North America was the largest region in the leukocyte adhesion deficiency management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the leukocyte adhesion deficiency management market report are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline PLC, Gilead Sciences Inc., Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd., Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc., Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.. For further insights on this market, request a sample here.

Major trends in this market include Advancements In Leukocyte Adhesion Deficiency Management Lentiviral Vector-Based Gene Therapy Shows Promising Results. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Leukocyte Adhesion Deficiency Management Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top
\
Back to top